NeoGenomics

Historical price data

NeoGenomics is a mission-driven company focused on transforming cancer care through advanced diagnostic testing and data solutions. Its core strategy leverages a comprehensive, multi-modal testing platform and one of the largest proprietary oncology genomic databases to serve healthcare providers, biopharma partners, and patients. With annual volumes exceeding 1.7 million tests and a growing emphasis on MRD detection and data services, the company is positioned at the intersection of diagnostics and real-world evidence in the expanding precision medicine market.

An integrated, multi-modal oncology diagnostics platform combining next-generation sequencing (NGS), liquid biopsy (RaDaR®), traditional methodologies (IHC, FISH, flow cytometry), and a proprietary real-world genomic database of over 2 million patient profiles.

NeoGenomics competes with large reference labs (Quest, LabCorp), specialized oncology diagnostics leaders (Foundation Medicine/Roche, Guardant Health), and academic medical centers. Its differentiation lies in its multi-modal breadth, established provider network, and integrated data asset from over 2 million patient profiles.